HERIZON-GEA-01: Zanidatamab + chemo ± tislelizumab for 1L treatment of HER2-positive gastroesophageal adenocarcinoma
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
HERIZON-GEA-01: Zanidatamab + chemo ± tislelizumab for 1L treatment of HER2-positive gastroesophageal adenocarcinoma
Authors
Keywords
-
Journal
Future Oncology
Volume 18, Issue 29, Pages 3255-3266
Publisher
Future Medicine Ltd
Online
2022-08-24
DOI
10.2217/fon-2022-0595
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Gastric Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology
- (2022) Jaffer A. Ajani et al. Journal of the National Comprehensive Cancer Network
- P-26 HERIZON-GEA-01: A phase 3 study of zanidatamab in combination with chemotherapy with or without tislelizumab in first-line human epidermal growth factor receptor 2 positive (HER2+) advanced/metastatic gastroesophageal adenocarcinoma (GEA)
- (2022) J. Tabernero et al. ANNALS OF ONCOLOGY
- Efficacy of Ipilimumab vs FOLFOX in Combination With Nivolumab and Trastuzumab in Patients With Previously Untreated ERBB2-Positive Esophagogastric Adenocarcinoma
- (2022) Alexander Stein et al. JAMA Oncology
- Zanidatamab (ZW25) in HER2-expressing gastroesophageal adenocarcinoma (GEA): Results from a phase I study.
- (2021) Funda Meric-Bernstam et al. JOURNAL OF CLINICAL ONCOLOGY
- Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2021) Hyuna Sung et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Is advanced esophageal adenocarcinoma a distinct entity from intestinal subtype gastric cancer? Data from the AGAMENON-SEOM Registry
- (2021) Felipe Alvarez-Manceñido et al. Gastric Cancer
- Biomarker-targeted therapies for advanced-stage gastric and gastro-oesophageal junction cancers: an emerging paradigm
- (2021) Yoshiaki Nakamura et al. Nature Reviews Clinical Oncology
- 1380P Phase (Ph) II study of zanidatamab + chemotherapy (chemo) in first-line (1L) HER2 expressing gastroesophageal adenocarcinoma (GEA)
- (2021) G. Ku et al. ANNALS OF ONCOLOGY
- Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study
- (2021) Jong-Mu Sun et al. LANCET
- First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial
- (2021) Yelena Y Janjigian et al. LANCET
- The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer
- (2021) Yelena Y. Janjigian et al. NATURE
- Tislelizumab: First Approval
- (2020) Arnold Lee et al. DRUGS
- Targeting HER2 in combination with anti-PD-1 and chemotherapy confers a significant tumor shrinkage of gastric cancer: A multi-institutional phase Ib/II trial of first-line triplet regimen (pembrolizumab, trastuzumab, chemotherapy) for HER2-positive advanced gastric cancer (AGC).
- (2020) Sun Young Rha et al. JOURNAL OF CLINICAL ONCOLOGY
- First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial
- (2020) Yelena Y Janjigian et al. LANCET ONCOLOGY
- Targeted therapies for gastroesophageal cancers
- (2020) Andrew Hsu et al. Annals of Translational Medicine
- First-line pembrolizumab/placebo plus trastuzumab and chemotherapy in HER2-positive advanced gastric cancer: KEYNOTE-811
- (2020) Hyun Cheol Chung et al. Future Oncology
- HER2/neu (ERBB2) expression and gene amplification correlates with better survival in esophageal adenocarcinoma
- (2019) Patrick Sven Plum et al. BMC CANCER
- KEYNOTE-811 pembrolizumab plus trastuzumab and chemotherapy for HER2+ metastatic gastric or gastroesophageal junction cancer (mG/GEJC): A double-blind, randomized, placebo-controlled phase 3 study.
- (2019) Yelena Yuriy Janjigian et al. JOURNAL OF CLINICAL ONCOLOGY
- Esophageal and Esophagogastric Junction Cancers, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology
- (2019) Jaffer A. Ajani et al. Journal of the National Comprehensive Cancer Network
- HER2-targeted therapies — a role beyond breast cancer
- (2019) Do-Youn Oh et al. Nature Reviews Clinical Oncology
- The binding of an anti-PD-1 antibody to FcγRΙ has a profound impact on its biological functions
- (2018) Tong Zhang et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- The roles of PD-1/PD-L1 and its signalling pathway in gastrointestinal tract cancers
- (2018) Chunguo Cui et al. CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY
- Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomised, placebo-controlled phase 3 study
- (2018) Josep Tabernero et al. LANCET ONCOLOGY
- Association of quality of life with disease characteristics and treatment outcomes in patients with advanced gastric cancer: Exploratory analysis of RAINBOW and REGARD phase III trials
- (2018) Ian Chau et al. EUROPEAN JOURNAL OF CANCER
- Health-related quality of life of esophageal cancer patients in daily life after treatment: A multicenter cross-sectional study in China
- (2018) Qian Liu et al. Cancer Medicine
- HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and the American Society of Clinical Oncology
- (2017) Angela N. Bartley et al. JOURNAL OF CLINICAL ONCOLOGY
- PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome
- (2017) Hashem O. Alsaab et al. Frontiers in Pharmacology
- Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†
- (2016) E. C. Smyth et al. ANNALS OF ONCOLOGY
- Oesophageal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†
- (2016) F. Lordick et al. ANNALS OF ONCOLOGY
- Metastatic Gastroesophageal Adenocarcinoma Patients Treated with Systemic Therapy Followed by Consolidative Local Therapy: A Nomogram Associated with Long-Term Survivors
- (2016) Hironori Shiozaki et al. ONCOLOGY
- Trastuzumab emtansine (T-DM1) renders HER2 + breast cancer highly susceptible to CTLA-4/PD-1 blockade
- (2015) Philipp Müller et al. Science Translational Medicine
- HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer
- (2014) Eric Van Cutsem et al. Gastric Cancer
- Comprehensive molecular characterization of gastric adenocarcinoma
- (2014) Adam J. Bass et al. NATURE
- Treatment of gastric cancer
- (2014) Michele Orditura WORLD JOURNAL OF GASTROENTEROLOGY
- Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy
- (2011) J. Stagg et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
- (2010) Yung-Jue Bang et al. LANCET
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started